Infliximab
- PDF / 169,693 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 54 Downloads / 127 Views
1 S
Exacerbation of plaque psoriasis: case report A 29-year-old man experienced severe exacerbation of plaque psoriasis after treatment with infliximab for Crohn’s disease. The man, who had a history of plaque psoriasis, was hospitalised and diagnosed with Crohn’s disease in February 2019. He had dermatological flares of cutaneous manifestations in the upper thorax, arms and legs, which were managed with unspecified topical steroids. He experienced his last dermatological exacerbation in 2014. One month after the discharge, he started receiving biologic therapy with infliximab [CT-P13] for extensive active ileal disease and achieved completed resolution of the symptoms (abdominal pain and diarrhoea). In January 2020, he was non-medically switched from biosimilar infliximab [CT-P13] to infliximab [SB2] infusion [dosage not stated]. A few days after the infliximab [SB2] infusion, he experienced severe exacerbation of his underlying psoriasis, with a diffuse onset of the typical plaques in the thorax, arms and abdomen [duration of treatment to reaction onset not stated]. The man received treatment with unspecified topical steroids, but did not see any improvement in the symptoms. Therefore, he was switched back to infliximab [CT-P13], which dramatically improved his dermatological symptoms. Within one month, the lesions resolved completely. The exacerbation of plaque psoriasis was thought to be related to infliximab [SB2]. Pagnini C, et al. Similar but not identical: Plaque psoriasis exacerbation in a patient with Crohn's disease after switching from ct-p13 to sb2 infliximab biosimilar. 803514375 Inflammatory Bowel Diseases 26: E83-E84, No. 8, Aug 2020. Available from: URL: http://doi.org/10.1093/ibd/izaa128
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
